Trial Profile
Phase I/II Study of Ixazomib in Combination With Pomalidomide, Clarithromycin and Dexamethasone (PiC-D) in Patients With Double Refractory Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Sep 2023
Price :
$35
*
At a glance
- Drugs Clarithromycin (Primary) ; Dexamethasone (Primary) ; Ixazomib (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 30 Aug 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 30 Aug 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Aug 2024.
- 07 Apr 2023 Planned End Date changed from 1 Jun 2023 to 1 Dec 2023.